Pharmacological enhancement of naltrexone treatment for opioid dependence: a review

References

• PaulozziLBudnitzDXiYIncreasing deaths from opioid analgesics in the United StatesPharmacoepidemiol Drug Saf2006159619627
   Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAM-HSA)Results from the 2009 national survey on drug use and health: volume I. Summary of national findingsRockville, MDOffice of Applied Studies, NSDUH2010
   Google Scholar
• FriedmannPDLemonSCSteinMDD’AunnoTAAccessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizationsHealth Serv Res200338388790312822917
   PubMed Web of Science ®Google Scholar
• PetersonJASchwartzRPMitchellSGWhy don’t out-of-treatment individuals enter methadone treatment programmes?Int J Drug Policy2010211364218805686
   PubMed Web of Science ®Google Scholar
• CaplehornJRHartelDMIrwigLMeasuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinicsSubst Use Misuse19973243994139090802
   PubMed Web of Science ®Google Scholar
• SchwartzRPKellySMO’GradyKEAttitudes toward buprenorphine and methadone among opioid-dependent individualsAm J Addict200817539640118770082
   PubMed Web of Science ®Google Scholar
• ZallerNDBazaziARVelazquezLRichJDAttitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparitiesInt J Environ Res Public Health20096278779719440415
   PubMed Web of Science ®Google Scholar
• ReeceADiffering age related trajectories of dysfunction in several organ systems in opiate dependenceAging Clin Exp Res2212011 [Epub ahead of print]
   Google Scholar
• ReeceADavidsonPDeficit of circulating stem – progenitor cells in opiate addiction: a pilot studySubst Abuse Treat Prev Policy200721917615060
   PubMed Web of Science ®Google Scholar
• ToskulkaoTPornchaiRAkkarapatumwongVVatanatunyakumSGovitrapongPAlteration of lymphocyte opioid receptors in methadone maintenance subjectsNeurochem Int201056228529019913582
   PubMed Web of Science ®Google Scholar
• LingWWessonDRClinical efficacy of buprenorphine: comparisons to methadone and placeboDrug Alcohol Depend2003702 SupplS49S5712738350
   PubMed Web of Science ®Google Scholar
• StenbackaMBeckOLeifmanARomelsjoAHelanderAProblem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatmentDrug Alcohol Rev2007261556317364837
   PubMed Web of Science ®Google Scholar
• ReeceAHypothalamic opioid-melanocortin appetitive balance and addictive cravingMed Hypotheses201176113213720926200
   PubMed Web of Science ®Google Scholar
• AdiYJuarez-GarciaAWangDOral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluationHealth Technol Assess2007116iiiiv18517280624
   PubMed Web of Science ®Google Scholar
• GonzalezGOlivetoAKostenTRCombating opiate dependence: a comparison among the available pharmacological optionsExpert Opin Pharmacother20045471372515102558
   PubMed Web of Science ®Google Scholar
• MinozziSAmatoLDavoliMDetoxification treatments for opiate dependent adolescentsCochrane Database Syst Rev2009152CD00674919370651
   PubMed Web of Science ®Google Scholar
• WiklerARequirements for extinction of relapse-facilitating variables and for rehabilitation in a narcotic-antagonist treatment programAdv Biochem Psychopharmacol1973803994144795072
   PubMedGoogle Scholar
• CornishJWMetzgerDWoodyGENaltrexone pharmacotherapy for opioid dependent federal probationersJ Subst Abuse Treat19971465295349437624
   PubMed Web of Science ®Google Scholar
• KleberHDPharmacologic treatments for opioid dependence: detoxification and maintenance optionsDialogues Clin Neurosci20079445547018286804
   PubMedGoogle Scholar
• O’BrienCCornishJWNaltrexone for probationers and paroleesJ Subst Abuse Treat200631210711116919734
   PubMed Web of Science ®Google Scholar
• WashtonAMGoldMSPottashACSuccessful use of naltrexone in addicted physicians and business executivesAdv Alcohol Subst Abuse19844289966524509
   PubMedGoogle Scholar
• BrewerCStreelELearning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive “immersion” methods of foreign language teachingSubst Abus200324315717312913365
   PubMedGoogle Scholar
• ReeceASPsychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant programSubst Abuse Treat Prev Policy200723518036213
   PubMed Web of Science ®Google Scholar
• FramDHMarmoJHoldenRNaltrexone treatment – the problem of patient acceptanceJ Subst Abuse Treat1989621191222746710
   PubMed Web of Science ®Google Scholar
• TennantFSJrRawsonRACohenAJMannAClinical experience with naltrexone in suburban opioid addictsJ Clin Psychiatry1984459 Pt 242456469935
   PubMed Web of Science ®Google Scholar
• GreensteinRAO’BrienCPMcLellanATNaltrexone: a short-term treatment for opiate dependenceAm J Drug Alcohol Abuse1981832913007340503
   PubMed Web of Science ®Google Scholar
• CrowleyTJWagnerJEZerbeGMacdonaldMNaltrexone-induced dysphoria in former opioid addictsAm J Psychiatry19851429108110842992300
   PubMed Web of Science ®Google Scholar
• HollisterLEJohnsonKBoukhabzaDGillespieHKAversive effects of naltrexone in subjects not dependent on opiatesDrug Alcohol Depend19818137417297411
   PubMed Web of Science ®Google Scholar
• DeanAJSaundersJBJonesRTYoungRMConnorJPLawfordBRDoes naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependenceJ Psychiatry Neurosci2006311384516496034
   PubMed Web of Science ®Google Scholar
• MiottoKMcCannMBaschJRawsonRLingWNaltrexone and dysphoria: fact or myth?Am J Addict200211215116012028745
   PubMed Web of Science ®Google Scholar
• MyselsDJChengWYNunesEVSullivanMAThe association between naltrexone treatment and symptoms of depression in opioid-dependent patientsAm J Drug Alcohol Abuse2011371222621192125
   PubMed Web of Science ®Google Scholar
• CarrollKMBallSANichCTargeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvementArch Gen Psychiatry200158875576111483141
   PubMed Web of Science ®Google Scholar
• PrestonKLSilvermanKUmbrichtADeJesusAMontoyaIDSchusterCRImprovement in naltrexone treatment compliance with contingency managementDrug Alcohol Depend199954212713510217552
   PubMed Web of Science ®Google Scholar
• NunesEVRothenbergJLSullivanMACarpenterKMKleberHDBehavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?Am J Drug Alcohol Abuse200632450351717127538
   PubMed Web of Science ®Google Scholar
• OslinDWLynchKGPettinatiHMA placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial interventionAlcohol Clin Exp Res20083271299130818540910
   PubMed Web of Science ®Google Scholar
• SullivanMAGarawiFBisagaAManagement of relapse in naltrexone maintenance for heroin dependenceDrug Alcohol Depend2007912–328929217681716
   PubMed Web of Science ®Google Scholar
• MartinWRJasinskiDRManskyPANaltrexone, an antagonist for the treatment of heroin dependence. Effects in manArch Gen Psychiatry19732867847914707988
   PubMed Web of Science ®Google Scholar
• O’BrienCPGreensteinRAMintzJWoodyGEClinical experience with naltrexoneAm J Drug Alcohol Abuse197523–43653771227298
   PubMed Web of Science ®Google Scholar
• LickoVOverview of human pharmacokinetics of naltrexoneNIDA Res Monogr1981281611716791002
   PubMedGoogle Scholar
• TurncliffRZDunbarJLDongQPharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairmentJ Clin Pharmacol200545111259126716239359
   PubMed Web of Science ®Google Scholar
• McCaulMEWandGSRohdeCLeeSMSerum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkersAlcohol Clin Exp Res20002491385139111003204
   PubMed Web of Science ®Google Scholar
• LeeMCWagnerHNJrTanadaSFrostJJBiceANDannalsRFDuration of occupancy of opiate receptors by naltrexoneJ Nucl Med1988297120712112839637
   PubMed Web of Science ®Google Scholar
• VerebeyKVolavkaJMuleSJResnickRBNaltrexone: disposition, metabolism, and effects after acute and chronic dosingClin Pharmacol Ther1976203315328954353
   PubMed Web of Science ®Google Scholar
• KoobGFLe MoalMAddiction and the brain antireward systemAnnu Rev Psychol200859295318154498
   PubMed Web of Science ®Google Scholar
• StrombergMFSengpielTMacklerSAVolpicelliJRO‘BrienCPVogelWHEffect of naltrexone on oral consumption of concurrently available ethanol and cocaine in the ratAlcohol200228316917912551758
   PubMed Web of Science ®Google Scholar
• SchmidtWKTamSWShotzbergerGSSmithDHJrClarkRVernierVGNalbuphineDrug Alcohol Depend1985143–43393622986929
   PubMed Web of Science ®Google Scholar
• McLeodRLParraLEMutterJCNociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptorsBr J Pharmacol200113261175117811250866
   PubMed Web of Science ®Google Scholar
• WnendtSKrugerTJanochaEHildebrandtDEnglbergerWAgonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assayMol Pharmacol199956233433810419552
   PubMed Web of Science ®Google Scholar
• OlsenLChristophersenASFrogopsahlGWaalHMorlandJPlasma concentrations during naltrexone implant treatment of opiate-dependent patientsBr J Clin Pharmacol200458221922215255807
   PubMed Web of Science ®Google Scholar
• RamenskayaGShikhEArzamastsevAKukesVMolecular biological problems of drug design and mechanism of drug action. Pharmacokinetic study of the new domestic hypodermic formof naltrexone: prodetoxon depot tabletsPharm Chem J200539113
   Google Scholar
• NgoHTArnold-ReedDEHanssonRCTaitRJHulseGKBlood naltrexone levels over time following naltrexone implantProg Neuropsychopharmacol Biol Psychiatry2008321232817651881
   PubMed Web of Science ®Google Scholar
• WaalHFrogopsahlGOlsenLChristophersenASMorlandJNaltrexone implants – duration, tolerability and clinical usefulness. A pilot studyEur Addict Res200612313814416778434
   PubMed Web of Science ®Google Scholar
• ColquhounRTanDYHullSA comparison of oral and implant naltrexone outcomes at 12 monthsJ Opioid Manag20051524925617319558
   PubMedGoogle Scholar
• FosterJBrewerCSteeleTNaltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levelsAddict Biol20038221121712850780
   PubMed Web of Science ®Google Scholar
• HulseGKArnold-ReedDEO’NeilGChanCTHanssonRO’NeilPBlood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implantsAddict Biol200491596515203440
   PubMed Web of Science ®Google Scholar
• KrupitskyEMBurakovAMDunaevskyIVRomanovaTNSlavinaTYGrinenkoAYSingle versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependenceJ Psychoactive Drugs2007391131917523581
   PubMed Web of Science ®Google Scholar
• CarrenoJEAlvarezCENarcisoGIBascaranMTDiazMBobesJMaintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependenceAddict Biol20038442943814690879
   PubMed Web of Science ®Google Scholar
• KunoeNLobmaierPVederhusJKRetention in naltrexone implant treatment for opioid dependenceDrug Alcohol Depend20101111–216616920570059
   PubMed Web of Science ®Google Scholar
• LintzerisNLeeSScopellitiLMabbuttJHaberPSUnplanned admissions to two Sydney public hospitals after naltrexone implantsMed J Aust2008188844144418429708
   PubMed Web of Science ®Google Scholar
• LobmaierPPKunoeNGossopMKatevollTWaalHNaltrexone implants compared to methadone: outcomes six months after prison releaseEur Addict Res201016313914520424458
   PubMed Web of Science ®Google Scholar
• NgoHTTaitRJArnold-ReedDEHulseGKMental health outcomes following naltrexone implant treatment for heroin-dependenceProg Neuropsychopharmacol Biol Psychiatry200731360561217229510
   PubMed Web of Science ®Google Scholar
• HulseGKMorrisNArnold-ReedDTaitRJImproving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexoneArch Gen Psychiatry200966101108111519805701
   PubMed Web of Science ®Google Scholar
• HulseGKNgoHTTaitRJRisk factors for craving and relapse in heroin users treated with oral or implant naltrexoneBiol Psychiatry201068329630220537615
   PubMed Web of Science ®Google Scholar
• KunoeNLobmaierPVederhusJKNaltrexone implants after in-patient treatment for opioid dependence: randomised controlled trialBr J Psychiatry2009194654154619478295
   PubMed Web of Science ®Google Scholar
• KrupitskyEZvartauEWoodyGUse of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not availableCurr Psychiatry Rep201012544845320640538
   PubMed Web of Science ®Google Scholar
• ComerSDCollinsEDKleberHDNuwayserESKerriganJHFischmanMWDepot naltrexone: long-lasting antagonism of the effects of heroin in humansPsychopharmacology (Berl)2002159435136011823887
   PubMed Web of Science ®Google Scholar
• GallowayGPKochMCelloRSmithDEPharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trialBMC Psychiatry200551815804355
   PubMed Web of Science ®Google Scholar
• JohnsonBANaltrexone long-acting formulation in the treatment of alcohol dependenceTher Clin Risk Manag20073574174918472999
   PubMedGoogle Scholar
• GastfriendDRIntramuscular extended-release naltrexone: current evidenceAnn N Y Acad Sci2011121614416621272018
   PubMed Web of Science ®Google Scholar
• DunbarJLTurncliffRZDongQSilvermanBLEhrichEWLasseterKCSingle- and multiple-dose pharmacokinetics of long-acting injectable naltrexoneAlcohol Clin Exp Res200630348049016499489
   PubMed Web of Science ®Google Scholar
• DunbarJLTurncliffRZHayesSCFarrellCBPopulation pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependenceJ Stud Alcohol Drugs200768686287017960304
   PubMed Web of Science ®Google Scholar
• FishmanMPrecipitated withdrawal during maintenance opioid blockade with extended release naltrexoneAddiction200810381399140118855831
   PubMed Web of Science ®Google Scholar
• SullivanMARothenbergJLVosburgSKPredictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trialAm J Addict200615215015916595353
   PubMed Web of Science ®Google Scholar
• FishmanMJWinstanleyELCurranEGarrettSSubramaniamGTreatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibilityAddiction201010591669167620626723
   PubMed Web of Science ®Google Scholar
• ComerSDSullivanMAYuEInjectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trialArch Gen Psychiatry200663221021816461865
   PubMed Web of Science ®Google Scholar
• BrooksACComerSDSullivanMALong-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experimentJ Clin Psychiatry201071101371137820673549
   PubMed Web of Science ®Google Scholar
• NgoHTTaitRJHulseGKComparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantationArch Gen Psychiatry200865445746518391134
   PubMed Web of Science ®Google Scholar
• ReeceASComparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphineJ Subst Abuse Treat200937325626519394789
   PubMed Web of Science ®Google Scholar
• TaitRJNgoHTHulseGKMortality in heroin users 3 years after naltrexone implant or methadone maintenance treatmentJ Subst Abuse Treat200835211612417931824
   PubMed Web of Science ®Google Scholar
• OnckenCVan KirkJKranzlerHRAdverse effects of oral naltrexone: analysis of data from two clinical trialsPsychopharmacology (Berl)2001154439740211349393
   PubMed Web of Science ®Google Scholar
• LobmaierPKornorHKunoeNBjorndalASustained-release naltrexone for opioid dependenceCochrane Database Syst Rev2008162CD00614018425938
   PubMed Web of Science ®Google Scholar
• GarbuttJCKranzlerHRO’MalleySSEfficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trialJAMA2005293131617162515811981
   PubMed Web of Science ®Google Scholar
• JohnsonBAAit-DaoudNAubinHJA pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependenceAlcohol Clin Exp Res20042891356136115365306
   PubMed Web of Science ®Google Scholar
• KranzlerHRWessonDRBillotLDrugAbuse Sciences Naltrexone Depot Study GroupNaltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trialAlcohol Clin Exp Res20042871051105915252291
   PubMed Web of Science ®Google Scholar
• HulseGKStalenbergVMcCallumDHistological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humansJ Control Release20051081435516154223
   PubMed Web of Science ®Google Scholar
• CroopRSFaulknerEBLabriolaDFThe safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study GroupArch Gen Psychiatry19975412113011359400350
   PubMed Web of Science ®Google Scholar
• KimSWGrantJEAdsonDERemmelRPA preliminary report on possible naltrexone and nonsteroidal analgesic interactionsJ Clin Psychopharmacol200121663263411763022
   PubMed Web of Science ®Google Scholar
• KimSWGrantJEYoonGWilliamsKARemmelRPSafety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatientsClin Neuropharmacol2006292777916614539
   PubMed Web of Science ®Google Scholar
• LuceyMRSilvermanBLIlleperumaAO’BrienCPHepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholicsAlcohol Clin Exp Res200832349850418241321
   PubMed Web of Science ®Google Scholar
• BrewerCWongVSNaltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literatureAddict Biol200491818715203443
   PubMed Web of Science ®Google Scholar
• MarkTMontejanoLKranzlerHChalkMGastfriendDComparison of healthcare utilization among patients treated with alcoholism medicationsAm J Manag Care2010161287988821348558
   PubMed Web of Science ®Google Scholar
• KostenTRKleberHDStrategies to improve compliance with narcotic antagonistsAm J Drug Alcohol Abuse19841022492666475891
   PubMed Web of Science ®Google Scholar
• MannelliPGottheilEBuonannoADe RisioSUse of very low-dose naltrexone during opiate detoxificationJ Addict Dis2003222637012703669
   PubMed Web of Science ®Google Scholar
• MannelliPPatkarAAPeindlKMurrayHWWuLTHubbardREffectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependenceJ Clin Psychopharmacol200727546847417873678
   PubMed Web of Science ®Google Scholar
• O’ConnorPGKostenTRRapid and ultrarapid opioid detoxification techniquesJAMA199827932292349438745
   PubMed Web of Science ®Google Scholar
• GibsonAEDegenhardtLJMortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial recordsDrug Alcohol Rev200726440541017564876
   PubMed Web of Science ®Google Scholar
• GibsonAEDegenhardtLJHallWDOpioid overdose deaths can occur in patients with naltrexone implantsMed J Aust2007186315215317309406
   PubMed Web of Science ®Google Scholar
• OliverPHorspoolMKeenJFatal opiate overdose following regimen changes in naltrexone treatmentAddiction2005100456056115784071
   PubMed Web of Science ®Google Scholar
• O’BrienBCodyCAnalgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challengeEur J Emerg Med200613531531616969243
   PubMed Web of Science ®Google Scholar
• StineSMKostenTRUse of drug combinations in treatment of opioid withdrawalJ Clin Psychopharmacol19921232032091629388
   PubMed Web of Science ®Google Scholar
• LandabasoMAIraurgiIJimenez-LermaJMA randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addictsAddiction19989357397449692272
   PubMed Web of Science ®Google Scholar
• KrupitskyEMZvartauEEMasalovDVNaltrexone with or without fluoxetine for preventing relapse to heroin addiction in St Petersburg, RussiaJ Subst Abuse Treat200631431932817084785
   PubMed Web of Science ®Google Scholar
• GerraGFertonaniGZaimovicAHostility in heroin abusers subtypes: fluoxetine and naltrexone treatmentProg Neuropsychopharmacol Biol Psychiatry1995198122512378868205
   PubMed Web of Science ®Google Scholar
• FarrenCKO’MalleySA pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependenceAm J Addict200211322823412202015
   PubMed Web of Science ®Google Scholar
• SinhaRKimmerlingADoebrickCKostenTREffects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findingsPsychopharmacology (Berl)2007190456957417136399
   PubMed Web of Science ®Google Scholar
• GerraGFantomaAZaimovicANaltrexone and buprenorphine combination in the treatment of opioid dependenceJ Psychopharmacol200620680681416401652
   PubMed Web of Science ®Google Scholar
• RothmanRBGorelickDAHeishmanSJAn open-label study of a functional opioid kappa antagonist in the treatment of opioid dependenceJ Subst Abuse Treat200018327728110742642
   PubMed Web of Science ®Google Scholar
• StellaLD’AmbraCMazzeoFNaltrexone plus benzodiazepine aids abstinence in opioid-dependent patientsLife Sci200577212717272215979652
   PubMed Web of Science ®Google Scholar
• PaniPPTroguEVaccaRAmatoLVecchiSDavoliMDisulfiram for the treatment of cocaine dependenceCochrane Database Syst Rev2010201CD00702420091613
   PubMedGoogle Scholar
• KleberHDKostenTRNaltrexone induction: psychologic and pharmacologic strategiesJ Clin Psychiatry1984459 Pt 229386469934
   PubMed Web of Science ®Google Scholar
• DijkstraBADe JongCABluschkeSMKrabbePFvan der StaakCPDoes naltrexone affect craving in abstinent opioid-dependent patients?Addict Biol200712217618217508990
   PubMed Web of Science ®Google Scholar
• HymanSMHongKIChaplinTMA stress-coping profile of opioid dependent individuals entering naltrexone treatment: a comparison with healthy controlsPsychol Addict Behav200923461361920025367
   PubMed Web of Science ®Google Scholar
• BennettDLalHDiscriminative stimuli produced by clonidine: an investigation of the possible relationship to adrenoceptor stimulation and hypotensionJ Pharmacol Exp Ther198222336426486292393
   PubMed Web of Science ®Google Scholar
• WeertsEGriffithsREvaluation of the intravenous reinforcing effects of clonidine in baboonsDrug Alcohol Depend199953320721410080046
   PubMed Web of Science ®Google Scholar
• McCannDJPotential of buprenorphine/naltrexone in treating poly-drug addiction and co-occurring psychiatric disordersClin Pharmacol Ther200883462763018212797
   PubMed Web of Science ®Google Scholar
• MannelliPPatkarAAPeindlKGorelickDAWuLTGottheilEVery low dose naltrexone addition in opioid detoxification: a randomized, controlled trialAddict Biol200914220421318715283
   PubMed Web of Science ®Google Scholar
• BrowerKJInsomnia, alcoholism and relapseSleep Med Rev20037652353915018094
   PubMed Web of Science ®Google Scholar
• KaplanGBHeinrichsSCCareyRJTreatment of addiction and anxiety using extinction approaches: neural mechanisms and their treatment implicationsPharmacol Biochem Behav201197361962520723558
   PubMed Web of Science ®Google Scholar
• VolkowNDWangGJFowlerJSTomasiDTelangFBalerRAddiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain’s control circuitBioessays201032974875520730946
   PubMed Web of Science ®Google Scholar
• KostenTRMorganCKleberHDPhase II clinical trials of buprenorphine: detoxification and induction onto naltrexoneNIDA Res Monogr19921211011191406906
   PubMedGoogle Scholar
• AkhondzadehSAhmadi-AbhariSAssadiSShabestariOKashaniAFarzanehganZDouble-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawalJ Clin Pharm Ther200025534735311123486
   PubMed Web of Science ®Google Scholar
• AssadiSMRadgoodarziRAhmadi-AbhariSABaclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]BMC Psychiatry200331614624703
   PubMed Web of Science ®Google Scholar
• GonzalezGSevarinoKSofuogluMTiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot studyAddiction200398111625163214616189
   PubMed Web of Science ®Google Scholar
• KheirabadiGRanjkeshMMaracyMSalehiMEffect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patientsAddiction200810391495149918783503
   PubMed Web of Science ®Google Scholar
• Martínez-RagaJSabaterAPerez-GalvezBCastellanoMCerveraGAdd-on gabapentin in the treatment of opiate withdrawalProg Neuropsychopharmacol Biol Psychiatry200428359960115093968
   PubMed Web of Science ®Google Scholar
• JiDGilpinNWRichardsonHNRivierCLKoobGFEffects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in ratsBehav Pharmacol200819111218195589
   PubMed Web of Science ®Google Scholar
• MyersKMCarlezonWAJrD-cycloserine facilitates extinction of naloxone-induced conditioned place aversion in morphine-dependent ratsBiol Psychiatry2009671858719782965
   PubMed Web of Science ®Google Scholar
• McCance-KatzEFSullivanLENallaniSDrug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a reviewAm J Addict201019141620132117
   PubMed Web of Science ®Google Scholar
• Saber-TehraniASBruceRDAlticeFLPharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependenceAm J Drug Alcohol Abuse201137111121247284
   PubMed Web of Science ®Google Scholar
• MannKHermannDIndividualised treatment in alcohol-dependent patientsEur ArchPsychiatry Clin Neurosci2010260Suppl 2S116120
   PubMed Web of Science ®Google Scholar
• OotemanWNaassilaMKoeterMWPredicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicatorsAddict Biol200914332833719523047
   PubMed Web of Science ®Google Scholar
• OlivaresJMPeuskensJPecenakJResselerSJacobsAAkhrasKSe-STAR Study GroupClinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registryCurr Med Res Opin20092592197220619604073
   PubMed Web of Science ®Google Scholar
• KaneJMEerdekensMLindenmayerJPKeithSJLesemMKarcherKLong-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychoticAm J Psychiatry200316061125113212777271
   PubMed Web of Science ®Google Scholar
• WeidenPRapkinBZygmuntAMottTGoldmanDFrancesAPostdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimenPsychiatr Serv19954610104910548829787
   PubMed Web of Science ®Google Scholar